Algeta

Alpharadin phase II trial extended for prostate cancer to U.K.

Published in Cancer Law Weekly, October 2nd, 2004

Algeta announced that the first U.K. patient has been included in a phase II study of the novel bone seeking radiopharmaceutical Alpharadin based on radium-223.

Alpharadin, an alpha particle emitting radiopharmaceutical, is being evaluated as a potential therapy of skeletal metastases. The recently initiated phase II randomized, placebo-controlled, multicenter trial will investigate the safety and efficacy of multiple injections of Alpharadin in prostate cancer patients. The study is the first formal clinical trial with an alpha particle emitter ever being conducted in the United Kingdom.

"We are extremely pleased to have extended our phase II...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Law Weekly

Source: Cancer Law Weekly (2004-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry